Interested in ODX shares? Here’s what you need to know

ODX shares have rallied wildly since the beginning of the coronavirus pandemic. But how sustainable is this rally? Anna Sokolidou tries to find out.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Omega Diagnostics Group (LSE:ODX) shares have had a wonderful time this year. They have rallied hefty 800% since the start of the pandemic! But how much further can the micro-cap rise from here?

ODX shares and their wild rally

As its name suggests, Omega Diagnostics Group specialises in providing medical testing equipment. As of writing, its market capitalisation is £104m. Although the ODX share price has recently gained a lot, it is still a micro-cap stock. Generally speaking, micro-caps are considered to be speculative investments. But let us look at the reasons for such a wild rally.

ODX has three operating segments. The first one specialises in allergies or food intolerances. The second department provides HIV testing equipment. The third one manufactures Covid-19 rapid tests. 

I am sure that the stock has rallied because of the rising demand for these tests. Earlier I wrote about Novacyt, a small biotechnology company, that also sells coronavirus tests. The stock market reacted in a very similar manner to its company rising sales. Novacyt’s other stock fundamentals, however, were quite pathetic.  

As I’ve said, micro-caps tend to be risky. At the same time, if you buy a micro-cap with sound fundamentals and a good future, you might end up getting a fortune from a small investment. So, let’s examine ODX shares in a bit more detail.

ODX fundamentals

The results for the year ended 31 March 2020, published on 14 July 2020, weren’t very impressive. 

Source: Omega Diagnostics Group 

Overall, in spite of the modest 12% sales rise, the loss for the year increased. Logically, the net cash flow declined too. As can be seen from the numbers above, the company is extremely small.

But the most recent news is really encouraging. ODX plans to sell 200,000 new coronavirus tests every week starting in October due to soaring demand. Given the company’s scale and size, it looks like a great revenue boost.

Here’s what I’d do

Although the performance improvement seems impressive, I wonder how sustainable the ODX shareholders’ party will be. There is still plenty of uncertainty regarding the pandemic. My own stance is rather cautiously pessimistic. True, I read a lot of positive news about the development of a Covid-19 vaccine. But it still looks like it will take a long while for a vaccine to be widely available. And even if that happens, it means the demand for Omega’s tests will fall.

On the positive side, ODX is well diversified. As I’ve mentioned, the company also specialises in HIV and food intolerance testing equipment. What’s more, it doesn’t focus on one country or one market. When demand for Covid-19 tests does fall, ODX can devote more resources to its other two departments. The good thing is that the Covid-19 tests will provide the company with a great deal more cash than it used to have. So, it will be in a better financial shape to operate after the end of the pandemic.

Still, if the demand for coronavirus tests plunges soon, many shareholders will get rid of their ODX shares. It will obviously lead to a sharp fall in the stock price. I’d personally avoid the stock and look for some other small-cap shares instead.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Anna Sokolidou has no position in any of the shares mentioned. The Motley Fool UK has no position in any of the shares mentioned. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Mixed-race female couple enjoying themselves on a walk
Investing Articles

A once-in-a-decade chance to get rich buying growth stocks?

We haven't seen a good spell for growth stocks for quite a few years now. But I reckon the signs…

Read more »

Young Asian man drinking coffee at home and looking at his phone
Investing Articles

The FTSE 100 is full of bargains! Here’s 1 stock I’m eyeing up

A weak economic outlook has hurt the FTSE 100. This Fool explains why she likes the look of this consumer…

Read more »

Investing Articles

2 no-brainer beginner FTSE 100 stocks to buy for my portfolio

Getting started with investing can be daunting. Here are two stocks for beginners to consider buying to build their first…

Read more »

Young black man looking at phone while on the London Overground
Investing Articles

2 recession-resistant UK shares investors should consider buying

Our writer details two UK shares she feels could withstand some of the ill-effects of the current malaise to provide…

Read more »

Tanker coming in to dock in calm waters and a clear sunset
Investing Articles

Glencore share price drops on results. Time to buy?

The Glencore share price wobbled a bit after a weak set of 2023 results. Here's why I have the stock…

Read more »

Mature Caucasian woman sat at a table with coffee and laptop while making notes on paper
Investing Articles

Big trouble in China sinks HSBC shares. Should I invest after record FY results?

HSBC shares have slumped following a disappointing end to 2023 for the FTSE stock. Royston Wild explains why this may…

Read more »

View of Tower Bridge in Autumn
Investing Articles

3 dirt cheap FTSE 100 shares to snap up today?

The FTSE 100 is rallying, but many shares still look super cheap on fundamentals. Is our writer buying these three…

Read more »

Black woman using loudspeaker to be heard
Investing Articles

FTSE 100 earnings: what can we expect from Rolls-Royce in 2024?

The Rolls-Royce share price tripled in 2023. Roland Head wonders whether this FTSE 100 stock could continue that impressive trajectory…

Read more »